ROBOSENSE
7.2.2020 15:02:12 CET | Business Wire | Press release
RoboSense, a leading automotive LiDAR manufacturer, announced today that it has obtained the IATF 16949 certificate in the automotive field, which now fully qualifies it to supply to automotive customers. RoboSense’s LiDAR production line obtained the IATF 16949 Letter of Conformity in December, which has accelerated partnerships of automotive-grade LiDAR serial productions with major OEMs and Tier 1s.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200207005157/en/
Developed by the IATF (International Automotive Task Force) and submitted to the International Organization for Standardization (ISO) for approval and publication, IATF 16949 is the most widely used global quality management standard for the automotive industry. In addition, the high quality management that IATF 16949 offers utilizes 5 tools (APQP/FMEA/MSA/SPC/PPAP) as part of their application assessment.
Dr. LeiLei Shinohara, the Co-partner and Vice President of RoboSense, said, "IATF16949 requires extremely high production consistency, and emphasizes various product reliability metrics. It recognizes the RoboSense design, research and development, and production processes. It also indicates that RoboSense has achieved a new milestone of complete readiness for serial mass production of automotive LiDARs, including the latest solid-state smart LiDAR "RS-LiDAR-M1".”
RoboSense's "125-layer equivalent" solid-state LiDAR "RS-LiDAR-M1" was officially released in January 2020 as the world’s first MEMS LiDAR to obtain IATF6949 for its production line. Its production was carried out under the IATF16949 quality management system.
The product development of "RS-LiDAR-M1" followed the APQP and A-SPICE as the basis for the project management and product development process. During production, RoboSense fully implemented the IATF16949 quality management system and ISO26262 functional safety standards. By combining ISO16750 test requirement and other automotive-grade reliability specifications with these systems, the accuracy of the RS-LiDAR-M1 product can be verified.
MEMS mirror is the core component in RS-LiDAR-M1. According to the AEC-Q100 standard, combining the characteristics of MEMS micro-mirror, a total of ten verification test groups were designed, covering factors such as: temperature, humidity, packaging process, electromagnetic compatibility, mechanical vibration and shock, and aging. The cumulative test time for all test samples has now exceeded 100,000 hours. Furthermore, the longest-running prototype has been tested for more than 300 days, while the total road test mileage has exceeded 150,000 kilometers with no degradation found in various testing scenarios.
In Vienna, Austria, the RS-LiDAR-M1 was tested for rain and fog under different light and wind speed conditions. The test results prove that the RS-LiDAR-M1 has met the required standards and the final mass-produced RS-LiDAR-M1 will adapt to all climate and working conditions.
RoboSense continues to optimize the LiDAR performance in order to lead the way towards a driverless future. On September 25, 2019, RoboSense partnered with First Automobile Works (FAW), the world's leading automotive OEM, to include RS-LiDAR-M1 as a core component in FAW's proprietary next-generation autonomous driving system development. On January 8, 2020, during CES2020, RoboSense cooperated with Freetech, the leading ADAS solution provider, on the serial production of the smart multi-sensor fusion solution.
About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems. By incorporating LiDAR sensors, AI algorithms and IC chipsets, conventional 3D LiDAR sensors are transformed to full data analysis and comprehension systems. The company's mission is to provide outstanding hardware and artificial intelligence capabilities to deliver smart solutions that enable robots (including vehicles) to have perception capability more superior to humans.
About IATF
IATF members include BMW Group, Daimler AG, FCA, Ford Motor Company, General Motors Company, Jaguar Land Rover (JLR) Limited, PSA Group, Renault, Volkswagen AG and the vehicle manufacturers respective trade associations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200207005157/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 09:20:00 CEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom